company background image
9989 logo

Shenzhen Hepalink Pharmaceutical Group SEHK:9989 Stock Report

Last Price

HK$4.60

Market Cap

HK$16.4b

7D

-1.5%

1Y

34.1%

Updated

22 May, 2025

Data

Company Financials +

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

SEHK:9989 Stock Report

Market Cap: HK$16.4b

9989 Stock Overview

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. More details

9989 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance1/6
Financial Health6/6
Dividends3/6

Rewards

Trading at 68.5% below our estimate of its fair value

Earnings are forecast to grow 14.28% per year

Became profitable this year

Risk Analysis

Large one-off items impacting financial results


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Shenzhen Hepalink Pharmaceutical Group
Historical stock prices
Current Share PriceCN¥4.60
52 Week HighCN¥5.92
52 Week LowCN¥3.02
Beta0.43
1 Month Change5.75%
3 Month Change1.10%
1 Year Change34.11%
3 Year Change-26.05%
5 Year Changen/a
Change since IPO-73.95%

Recent News & Updates

Recent updates

Shareholder Returns

9989HK PharmaceuticalsHK Market
7D-1.5%8.8%1.6%
1Y34.1%20.4%14.8%

Return vs Industry: 9989 exceeded the Hong Kong Pharmaceuticals industry which returned 20.4% over the past year.

Return vs Market: 9989 exceeded the Hong Kong Market which returned 14.8% over the past year.

Price Volatility

Is 9989's price volatile compared to industry and market?
9989 volatility
9989 Average Weekly Movement5.4%
Pharmaceuticals Industry Average Movement7.6%
Market Average Movement8.0%
10% most volatile stocks in HK Market15.3%
10% least volatile stocks in HK Market4.2%

Stable Share Price: 9989 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 9989's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19981,926Yu Shanwww.hepalink.com

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates through four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Fundamentals Summary

How do Shenzhen Hepalink Pharmaceutical Group's earnings and revenue compare to its market cap?
9989 fundamental statistics
Market capHK$16.44b
Earnings (TTM)HK$704.04m
Revenue (TTM)HK$5.73b
25.8x
P/E Ratio
3.2x
P/S Ratio

Is 9989 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
9989 income statement (TTM)
RevenueCN¥5.28b
Cost of RevenueCN¥3.63b
Gross ProfitCN¥1.65b
Other ExpensesCN¥998.50m
EarningsCN¥648.29m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)0.44
Gross Margin31.19%
Net Profit Margin12.28%
Debt/Equity Ratio28.7%

How did 9989 perform over the long term?

See historical performance and comparison

Dividends

2.2%
Current Dividend Yield
57%
Payout Ratio

Does 9989 pay a reliable dividends?

See 9989 dividend history and benchmarks
When do you need to buy 9989 by to receive an upcoming dividend?
Shenzhen Hepalink Pharmaceutical Group dividend dates
Ex Dividend DateMay 26 2025
Dividend Pay DateJul 22 2025
Days until Ex dividend3 days
Days until Dividend pay date60 days

Does 9989 pay a reliable dividends?

See 9989 dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/22 18:47
End of Day Share Price 2025/05/22 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lei TianAJ Securities Co., Ltd
Peng YanChangjiang Securities Co. LTD.
Wai Ming KongDBS Bank Ltd